Drug Trial Radar · NCT04669028
A Phase 3 Study of NE3107 in Probable Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Nov 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
439
Actual
Start
Aug 5, 2021
Primary completion
Sep 30, 2023
Study completion Oct 25, 2023
Sponsor
- Lead sponsor
- BioVie Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
U.S. multicenter, parallel group study designed to evaluate the safety and efficacy of oral 20 mg twice daily (BID) NE3107 vs placebo in 400 adult subjects with mild to moderate probable AD. Dual co-primary endpoints (Clinical Dementia Rating Scale Sum of Boxes, CDR-SB and ADAS-Cog12) will be evaluated as the change from Baseline to Week 30. Secondary endpoints include measures of cognition, neuropsychological deficits, functional performance, and glycemic control. A subset of patients may volunteer for exploratory magnetic resonance imaging (volumetric changes) and positron emission tomography (cortical glucose metabolic rate) scans at baseline and week 30.
Conditions
- Alzheimer Disease
Interventions
NE3107Drug
NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Alzheimer's disease.
PlaceboDrug
capsules that do not contain NE3107
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)Time frame: baseline and week 30 (end of study)
- Change in Alzheimer's Disease Assessment Scale Cognitive Subscale 12 [ADAS Cog12]Time frame: baseline and week 30 (end of study)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Ohio State University
Columbus, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.